We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Olema Pharmaceuticals Inc | NASDAQ:OLMA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.33 | 3.78% | 9.06 | 8.79 | 9.64 | 9.07 | 8.51 | 8.82 | 625,146 | 01:00:00 |
BofA Securities Health Care Conference 2024Date: Tuesday, May 14, 2024, at 4:35 p.m. PTLocation: Encore Hotel in Las Vegas, NVFormat: Presentation
H.C. Wainwright 2nd Annual BioConnect Investor ConferenceDate: Monday, May 20, 2024, at 4:00 p.m. ETLocation: NASDAQ Headquarters in New York, NYFormat: Fireside Chat
UBS Spring Biotech SymposiumDate: Tuesday, May 21, 2024Location: New York, NYFormat: One-on-one Meetings
TD Cowen 5th Annual Oncology Innovation SummitDate: Tuesday, May 28, 2024, at 10:00 a.m. ETLocation: VirtualFormat: Fireside Chat
Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days.
About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Contact:Geoffrey Mogilner, Vice President, Investor Relations and Communicationsir@olema.com
1 Year Olema Pharmaceuticals Chart |
1 Month Olema Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions